Clinical Trial

Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-14.
Status change: Not Yet Recruiting → Recruiting 2025-01-26
Trial Details
NCT Number NCT06643793
Lead Sponsor Affiliated Hospital of Nantong University
Conditions Colorectal Neoplasms Malignant
Enrollment 30 participants
Start Date 2024-11-04
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-28